Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 821,485 shares, an increase of 120.0% from the April 15th total of 373,385 shares. Currently, 17.4% of the company’s stock are short sold. Based on an average daily volume of 52,694,940 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

ASBP has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aspire Biopharma currently has an average rating of “Sell”.

Institutional Investors Weigh In On Aspire Biopharma

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC boosted its stake in shares of Aspire Biopharma by 2,252.1% during the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock worth $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd boosted its stake in shares of Aspire Biopharma by 853.2% during the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Aspire Biopharma during the third quarter worth about $28,000. Institutional investors and hedge funds own 19.17% of the company’s stock.

Aspire Biopharma Stock Down 4.4%

NASDAQ:ASBP opened at $5.61 on Friday. The stock’s 50 day moving average price is $20.67 and its 200 day moving average price is $90.13. The company has a market capitalization of $936,870.00, a PE ratio of -0.28 and a beta of 0.21. Aspire Biopharma has a 52-week low of $3.31 and a 52-week high of $1,050.36.

Aspire Biopharma (NASDAQ:ASBP) last announced its earnings results on Friday, May 15th. The company reported ($20.57) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.